AUG 24, 2020 11:30 AM PDT

FDA Grants Emergency Approval for Blood Plasma to Treat COVID-19

WRITTEN BY: Annie Lennon

The US Food and Drug Agency (FDA) has given emergency approval for expanded use of antibody-rich blood plasma to help those hospitalized with COVID-19. While President Donald Trump remains highly optimistic about the treatment, others remain skeptical of its effectiveness. 

Nevertheless, the decision will broaden the usage of the treatment, already administered to over 70,000 patients. Unlike a new drug, however, blood plasma cannot be manufactured in millions of doses- its availability is dependent on blood donations. As such, President Trump has urged people who have recovered from the virus to donate their blood via a nationwide campaign organized to collect it. 

Despite some optimism around the treatment, some warn that no randomized trials have confirmed its efficacy. Regardless, from data collected so far from over a dozen studies, the FDA says that it is ‘reasonable to believe that the treatment may be effective in lessening the severity or shortening the length of COVID-19 illness in some hospitlized patients’, should they receive it early enough. 

According to Dr. Peter Marks, a director at the FDA, patients who received plasma with a high level of antibodies within three days of being diagnosed, and provided they were not on a respirator, were 35% more likely to be alive a month after the treatment than those who received plasma with a low level of antibodies. This was only true for patients under 80 years old, however. 

Meanwhile, health authorities around the world remain uncertain about the treatment and its efficacy. The World Health Organization, for example, says that it is still ‘experimental’ and that the evidence base is so far too small to report meaningful results. In the same vein, Jonathan Reiner, a professor of medicine at George Washington University, called approval of the treatment a ‘political stunt’. 

Sources: New York TimesBBC

About the Author
  • Science writer with keen interests in technology and behavioral biology. Her current focus is on the interplay between these fields to create meaningful interactions, applications and environments.
You May Also Like
SEP 29, 2020
Cardiology
Improving Acute Myocardial Ischemia Treatment with Nitro Fatty Acids
SEP 29, 2020
Improving Acute Myocardial Ischemia Treatment with Nitro Fatty Acids
Acute myocardial ischemia occurs when blood flow is restricted in the heart. This usually leads to cardiovascular issues ...
OCT 16, 2020
Drug Discovery & Development
FDA Warns Against NSAIDs After Week 20 of Pregnancy
OCT 16, 2020
FDA Warns Against NSAIDs After Week 20 of Pregnancy
The US Food and Drug Administration (FDA) has warned against using nonsteroidal anti-inflammatory drugs (NSAIDs) from 20 ...
OCT 20, 2020
Drug Discovery & Development
New Treatment Reverses Late Stage Type 2 Diabetes
OCT 20, 2020
New Treatment Reverses Late Stage Type 2 Diabetes
Researchers from the Netherlands have developed a minimally invasive therapeutic procedure that allows people to discont ...
OCT 21, 2020
Drug Discovery & Development
Experimental Vaccine Shows Promise in Halting Alzheimer's
OCT 21, 2020
Experimental Vaccine Shows Promise in Halting Alzheimer's
In a preclinical study, researchers from the Univerity of South Florida have found that a vaccine that targets neurotoxi ...
OCT 06, 2020
Drug Discovery & Development
Drug For A Severe E. Coli Infection
OCT 06, 2020
Drug For A Severe E. Coli Infection
Escherichia coli, known as E. coli, is a popular bacterium associated with food poisoning and depending on the strain ca ...
OCT 18, 2020
Drug Discovery & Development
Virus-Mimicking Drug
OCT 18, 2020
Virus-Mimicking Drug
Scientists have found drug that a drug activates the body’s immune system by behaving like a virus and may make ce ...
Loading Comments...